Logo image of MURA

MURAL ONCOLOGY PLC (MURA) Stock Fundamental Analysis

NASDAQ:MURA - Nasdaq - IE000LK2BOB4 - Common Stock - Currency: USD

2.76  -0.22 (-7.38%)

After market: 2.6764 -0.08 (-3.03%)

Fundamental Rating

2

MURA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. While MURA has a great health rating, there are worries on its profitability. MURA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MURA has reported negative net income.
In the past year MURA has reported a negative cash flow from operations.
MURA Yearly Net Income VS EBIT VS OCF VS FCFMURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

MURA has a Return On Assets of -75.87%. This is in the lower half of the industry: MURA underperforms 67.74% of its industry peers.
MURA has a Return On Equity (-91.47%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -75.87%
ROE -91.47%
ROIC N/A
ROA(3y)-235.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MURA Yearly ROA, ROE, ROICMURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

MURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MURA Yearly Profit, Operating, Gross MarginsMURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, MURA has more shares outstanding
There is no outstanding debt for MURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MURA Yearly Shares OutstandingMURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M
MURA Yearly Total Debt VS Total AssetsMURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MURA has an Altman-Z score of -2.04. This is a bad value and indicates that MURA is not financially healthy and even has some risk of bankruptcy.
MURA's Altman-Z score of -2.04 is in line compared to the rest of the industry. MURA outperforms 53.83% of its industry peers.
MURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.04
ROIC/WACCN/A
WACCN/A
MURA Yearly LT Debt VS Equity VS FCFMURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

MURA has a Current Ratio of 5.84. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.
MURA has a Current ratio of 5.84. This is in the better half of the industry: MURA outperforms 62.39% of its industry peers.
MURA has a Quick Ratio of 5.84. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 5.84, MURA is doing good in the industry, outperforming 62.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.84
Quick Ratio 5.84
MURA Yearly Current Assets VS Current LiabilitesMURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

MURA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.02%, which is quite impressive.
EPS 1Y (TTM)39.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MURA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.94% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.05%
EPS Next 2Y30.42%
EPS Next 3Y21.38%
EPS Next 5Y11.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MURA Yearly Revenue VS EstimatesMURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M
MURA Yearly EPS VS EstimatesMURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MURA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MURA Price Earnings VS Forward Price EarningsMURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MURA Per share dataMURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

MURA's earnings are expected to grow with 21.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.42%
EPS Next 3Y21.38%

More info and screens

0

5. Dividend

5.1 Amount

MURA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MURAL ONCOLOGY PLC

NASDAQ:MURA (5/21/2025, 4:16:42 PM)

After market: 2.6764 -0.08 (-3.03%)

2.76

-0.22 (-7.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-20 2025-05-20
Earnings (Next)N/A N/A
Inst Owners67.28%
Inst Owner ChangeN/A
Ins Owners1.12%
Ins Owner Change25.92%
Market Cap47.67M
Analysts78
Price Target5.1 (84.78%)
Short Float %6.11%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.78%
Min EPS beat(2)-0.88%
Max EPS beat(2)-0.67%
EPS beat(4)2
Avg EPS beat(4)8.66%
Min EPS beat(4)-0.88%
Max EPS beat(4)32.18%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.67%
PT rev (3m)-69.23%
EPS NQ rev (1m)2.49%
EPS NQ rev (3m)-5.67%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)-14.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-7.72
EYN/A
EPS(NY)-5.45
Fwd EYN/A
FCF(TTM)-7.45
FCFYN/A
OCF(TTM)-7.44
OCFYN/A
SpS0
BVpS8.14
TBVpS8.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.87%
ROE -91.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-235.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.84
Quick Ratio 5.84
Altman-Z -2.04
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)167.92%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.71%
EPS Next Y28.05%
EPS Next 2Y30.42%
EPS Next 3Y21.38%
EPS Next 5Y11.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.38%
EBIT Next 3Y17.17%
EBIT Next 5Y8.57%
FCF growth 1Y34.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.82%
OCF growth 3YN/A
OCF growth 5YN/A